Subscribe to RSS - ASP


OIG: ASP continues to exceed AMP for certain drugs


WASHINGTON – The average sales price for 11 drug codes in the third quarter of 2019 met CMS’s price substitution criteria by exceeding the average manufacturer price by 5% for two consecutive quarters or three of the previous four quarters, according to a

OIG recommends CMS review Part B drug prices


WASHINGTON – The average sales price for 10 drug codes for the fourth quarter of 2018 exceeded the average manufacture price by 5% or more for two consecutive quarters, according to a new report from the Of

NHIA responds to OIG report on infusion payments


ALEXANDRIA, Va. – A recent Office of Inspector General report on payment for Part B DME infusion drugs is far too narrow to be the basis for new policy, according to the National Home Infusion Association.

ASP rises for several drugs


BALTIMORE – Fourth-quarter payments showed healthy increases for several respiratory drugs. Brand name drugs Brovana (J7605) rose 88 cents to $8.08 per dose and Perforomist (J7606) rose 40 cents to $8.88 per dose.

OIG: CMS overpays for infusion drugs


WASHINGTON – CMS could have saved $251 million over an 18-month period if it paid for DME infusion drugs using an average sales price methodology, according to a new report from the Office of Inspector General.

ASP: Budesonide back down


BALTIMORE – Pricing for budesonide took a plunge in the latest average sales price (ASP) figures for respiratory medications released in March.

In brief: ResMed lawsuit, surety bond update


SAN DIEGO – ResMed has sued Taiwanese manufacturer Apex Medical and its U.S. distributor, Medical Depot, doing business as Drive Medical, to stop alleged patent infringement. ResMed has filed parallel legal actions in the International Trade Commission (ITC) and U.S.